Evidence map›Paper›PMID 41252387›Full record

ArticlePLoS neglected tropical diseases2025

Making post-exposure prophylaxis effective for leprosy elimination: Insights from a multi-country study on low-endemic settings.

Stephanie M Tess van der Putten Hadik, Anil Fastenau, Anne Schoenmakers, Nimer Ortuño-Gutiérrez, Ricky Janssen

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Stephanie M Tess van der Putten HadikSchool of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, United Kingdom.
Anil FastenauGerman Leprosy and Tuberculosis Relief Association (DAHW), Wuerzburg, Germany.
Anne SchoenmakersNLR International, Amsterdam, the Netherlands.
Nimer Ortuño-GutiérrezEnabel - Belgian Agency for International Cooperation, Niamey, Niger.
Ricky JanssenDepartment of Health, Ethics & Society, Maastricht University, Maastricht, the Netherlands.ORCID 0000-0002-4485-1152

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Countries with low endemicity for leprosy face context-specific challenges in interrupting the transmission of Mycobacterium (M.) leprae to reach subsequent non-endemic status. This study explores the tensions and synergies that arise in resource-limited, low endemic settings when implementing and scaling-up single dose rifampicin (SDR) post-exposure prophylaxis (PEP) for leprosy control and elimination. We conducted 12 semi-structured in-depth interviews with key informants across six countries on the challenges and enablers in active case detection (ACD) and SDR-PEP implementation in low endemic countries. Key informants included medical practitioners, programme coordinators, researchers, policy makers, and experts, all with experience in PEP. Findings showed that lowering endemicity led to a fall in disease prioritization, lower levels of disease awareness within policy and healthcare practice, and the challenge of limited funding and resource accessibility. Advocating for leadership in leprosy control within national government and policy was central to long-term SDR-PEP implementation success, allowing for local alignment of policy and greater flexibility to adjust to changing disease patterns, resource availability and population health needs and priorities. Strengthening active coordination between stakeholders, both nationally and internationally, is vital for rifampicin procurement and supporting the integration of PEP into routine programmes. If the interruption of M. leprae transmission - and eventually leprosy disease elimination - is to be achieved, low endemic settings must also be considered in policy and practice. Our results provide key considerations for improving SDR-PEP implementation, specific to low endemic settings.

Indexed as

Disease EradicationLeprostatic AgentsLeprosyPost-Exposure ProphylaxisRifampinEndemic DiseasesHumansMycobacterium lepraeLeprostatic AgentsRifampin

Identifiers

PMID41252387
PMCPMC12626255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.